Pneumococcal Disease Pipeline Analysis: 05+ Companies are Working to Improve the Treatment Space | DelveInsight

 Breaking News
  • No posts were found

Pneumococcal Disease Pipeline Analysis: 05+ Companies are Working to Improve the Treatment Space | DelveInsight

October 17
21:24 2022
Pneumococcal Disease Pipeline Analysis: 05+ Companies are Working to Improve the Treatment Space | DelveInsight

DelveInsight’s, “Pneumococcal Disease Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Pneumococcal Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

 

Key takeaways from Pneumococcal Disease Pipeline Report

  • DelveInsight’s Pneumococcal Disease Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Pneumococcal Disease treatment.
  • The leading Pneumococcal Disease Companies include Pfizer, Affinivax, Merck Sharp &Dohme Corp., Vaxcyte, SK Chemicals, and others
  • The promising Pneumococcal Disease Therapies include V114, PNEUMOVAX™23, 20vPnC, 13vPnC, PPSV23, and others
  • The companies and academics are working to assess challenges and seek opportunities that could influence Pneumococcal Disease R&D. The therapies under development are focused on novel approaches to treat/improve Pneumococcal Disease.

 

Get an overview of the Pneumococcal Disease Pipeline landscape @ Pneumococcal Disease Emerging Therapies

 

Pneumococcal Disease Overview

Pneumococcal disease is an infection caused by the bacteria Streptococcus pneumoniae or pneumococcus. Disease is most common at the extremes of age, i.e, in young children and among the elderly. There are two main types of pneumococcal disease: noninvasive and invasive with noninvasive being the less serious. Non Invasive Pneumococcal disease: it occurs outside the major organs of the blood and the bacteria can cause- Bronchitis, Sinusitis. Invasive pneumococcal diseases: Invasive pneumococcal diseases (IPDs) are more serious than the noninvasive type and occur inside a major organ or in a person’s blood and the bacteria can cause: Pneumonia, Meningitis and sepsis. S. pneumoniae bacteria are common in the throat and nose. Bacteria can spread through droplets in the air and do not spread through contaminated food or water.

 

Latest Breakthroughs and Developments in the Pneumococcal Disease Treatment Landscape

  • Pfizer’s 20vPnC vaccine candidate includes capsular polysaccharide conjugates for the 13 serotypes already included in Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine[Diphtheria CRM197 Protein]). The vaccine also contains capsular polysaccharide conjugates for seven additional serotypes that cause invasive pneumococcal disease. U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for 20vPnC for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine candidate in adults age 18 years or older. If approved, 20vPnC will cover more serotypes responsible for the majority of pneumococcal disease than any other pneumococcal conjugate vaccine currently licensed or currently in late-stage clinical development. Importantly, 20vPnC has shown to induce immune memory, which provides protection and efficacy against non-bacteremic pneumonia, particularly in older adults.
  • ASP3772 utilizes the Multiple Antigen Presenting System (MAPS) platform which is Affinivax’s proprietary, next-generation vaccine technology. MAPS vaccine can present both the polysaccharide and the protein antigens to the host immune system to induce both a B- and T-cell immune response. ASP3772 is a vaccine candidate that offers the potential to provide broader protection against pneumococcal disease. It is currently in phase II stage of development by Affinivax partnership with Astellas Pharma Inc., includes 24 pneumococcal serotypes.

 

Pneumococcal Disease Emerging Drugs

  • 20 Valent Pneumococcal conjugate vaccine (20vPnC): Pfizer
  • ASP3772: Affinivax

 

Get to know more information about Pneumococcal Disease treatment therapies @ Pneumococcal Disease Clinical Trials

 

Pneumococcal Disease Pipeline Therapeutics Analysis

There are approx. 5+ key companies which are developing the therapies for Pneumococcal Disease. The companies which have their Pneumococcal Disease drug candidates in the most advanced stage, i.e. pre-registration include, Pfizer.

 

DelveInsight’s Pneumococcal Disease Pipeline Report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Discover more about therapy set to grab substantial Pneumococcal Disease Pipeline landscape @ Pneumococcal Disease Pipeline Therapeutics Assessment

 

Scope of the Pneumococcal Disease Pipeline Report

  • Coverage- Global
  • Pneumococcal Disease Companies- Pfizer, Affinivax, Merck Sharp &Dohme Corp., Vaxcyte, SK Chemicals and others
  • Pneumococcal Disease Therapies- V114, PNEUMOVAX™23, 20vPnC, 13vPnC, PPSV23, and others
  • Pneumococcal Disease Pipeline Assessment by Product Type
  • Pneumococcal Disease Pipeline Assessment by Stage and Product Type
  • Pneumococcal Disease Pipeline Assessment by Route of Administration
  • Pneumococcal Disease Pipeline Assessment by Stage and Route of Administration
  • Pneumococcal Disease Pipeline Assessment by Molecule Type
  • Pneumococcal Disease Pipeline Assessment by Stage and Molecule Type

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pneumococcal Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pneumococcal Disease – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Pneumococcal Disease Collaboration Deals
  9. Late Stage Products (Pre-registration)
  10. 20vPnC: Pfizer
  11. Mid Stage Products (Phase II)
  12. ASP3772: Affinivax
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Inactive Products
  16. Pneumococcal Disease Key Companies
  17. Pneumococcal Disease Key Products
  18. Pneumococcal Disease- Unmet Needs
  19. Pneumococcal Disease- Market Drivers and Barriers
  20. Pneumococcal Disease- Future Perspectives and Conclusion
  21. Pneumococcal Disease Analyst Views
  22. Pneumococcal Disease Key Companies
  23. Appendix

 

Got Queries? Reach out for more information on the Pneumococcal Disease Pipeline Report @ Pneumococcal Disease Preclinical and Discovery Stage Products

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

Related Articles

Categories